Pipeline

Differentiated Pharmaceutical Solutions

Harrow’s pipeline is strategically focused on the development and commercialization of differentiated pharmaceutical therapies designed to address unmet needs in eye care and related adjacent markets while expanding patient access to essential disease management solutions that improve clinical outcomes. The Company’s portfolio is weighted toward late-stage and near-commercial assets with demonstrated clinical utility, clear regulatory pathways, and compelling commercial profiles.

Harrow advances its pipeline through a disciplined, capital-efficient development strategy that prioritizes risk management and speed to market. By selectively investing in assets with reduced clinical and regulatory uncertainty and executing with a streamlined operational model, Harrow efficiently progresses products toward approval and commercialization, supporting sustainable growth and long-term value creation.